This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

CTI BioPharma Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 0/6

CTI BioPharma şirketinin toplam hissedar öz sermayesi $-25.3M ve toplam borcu $116.5M olup, bu da borç-öz sermaye oranını -459.4% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $112.3M ve $137.6M dir.

Anahtar bilgiler

-459.4%

Borç/özkaynak oranı

US$116.46m

Borç

Faiz karşılama oranı	n/a
Nakit	US$59.01m
Eşitlik	-US$25.35m
Toplam yükümlülükler	US$137.62m
Toplam varlıklar	US$112.27m

Son finansal sağlık güncellemeleri

Recent updates

CTI BioPharma: Reiterating Target Price Of $17 After Successful VONJO Launch

Aug 17

CTI BioPharma GAAP EPS of -$0.21 misses by $0.01, revenue of $12.33M beats by $3.23M

Aug 08

CTI BioPharma: Approval Is Great, Now There's The Follow Through

Jul 19

CTI BioPharma initiated at outperform at Cowen on potential for Vonjo for myelofibrosis

Jul 07

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: CTIC negatif hissedar özkaynağı var; bu, kısa vadeli varlıkların kısa vadeli yükümlülükleri karşılamamasından daha ciddi bir durumdur.

Uzun Vadeli Yükümlülükler: CTIC şirketinin negatif özkaynağı bulunmaktadır; bu, kısa vadeli varlıkların uzun vadeli yükümlülükleri karşılamamasından daha ciddi bir durumdur.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: CTIC negatif hissedar özkaynağı var ki bu yüksek borç seviyesinden daha ciddi bir durumdur.

Borcun Azaltılması: CTIC 'in negatif özkaynağı var, dolayısıyla borcunun zaman içinde azalıp azalmadığını kontrol etmemize gerek yok.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: CTIC şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: CTIC un, serbest nakit akışı her yıl % 16.9 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

This company listing is no longer active

CTI BioPharma Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 0/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

CTI BioPharma Corp. Contemplates Bankruptcy

CTI BioPharma Corp. Contemplates Bankruptcy

CTI BioPharma Corp. Contemplates Bankruptcy

CTI BioPharma Corp. Contemplates Bankruptcy

CTI BioPharma Corp. Contemplates Bankruptcy

Recent updates

CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from NASDAQ Composite Index

Swedish Orphan Biovitrum AB (publ) (OM:SOBI) completed the acquisition of CTI BioPharma Corp. (NasdaqCM:CTIC) from a group of shareholders.

CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from S&P TMI Index

CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from Russell Small Cap Comp Value Index

Swedish Orphan Biovitrum AB (publ) (OM:SOBI) entered into a definitive agreement and plan of merger to acquire CTI BioPharma Corp. (NasdaqCM:CTIC) from a group of shareholders for $1.2 billion.

CTI BioPharma Corp. to Report Q3, 2022 Results on Nov 07, 2022

CTI BioPharma Corp. Announces Executive Changes

CTI BioPharma Corp. Announces Presentation of New Anemia Benefit Data from Pacritinib Program At the Society of Hematologic Oncology Tenth Annual Meeting

CTI BioPharma: Reiterating Target Price Of $17 After Successful VONJO Launch

CTI BioPharma Corp. Contemplates Bankruptcy

CTI BioPharma GAAP EPS of -$0.21 misses by $0.01, revenue of $12.33M beats by $3.23M

CTI BioPharma Corp. to Report Q2, 2022 Results on Aug 08, 2022

CTI BioPharma: Approval Is Great, Now There's The Follow Through

CTI BioPharma initiated at outperform at Cowen on potential for Vonjo for myelofibrosis

CTI BioPharma - 3.2x Potential Upside On A De-Risked Asset

CTI BioPharma Corp., Annual General Meeting, Jun 01, 2022

National Comprehensive Cancer Network Recommends CTI BioPharma Corp.'s VONJO™ (pacritinib) for the Treatment of Myeloproliferative Neoplasms

CTI BioPharma Corp.: Pacritinib Approval, Downgrade To A Sell Rating

CTI BioPharma Corp. Contemplates Bankruptcy

CTI BioPharma Corp. appoints James K. Fong as senior vice president and chief commercial officer

CTI BioPharma Corp. Announces FDA Accelerated Approval of VONJO™ (pacritinib) for the Treatment of Adult Patients with Myelofibrosis and Thrombocytopenia

CTI BioPharma: A Speculative Buy Into The PDUFA Date

CTI BioPharma: Long And Troubled History, Finally Approaching Approval

CTI BioPharma Corp. Announces Extension of FDA Review Period for Pacritinib in Myelofibrosis with Severe Thrombocytopenia

CTI BioPharma Corp. Announces Acceptance of NDA Granted with Priority Review of Pacritinib for Treatment of Patients with Myelofibrosis

FDA grants 'priority review' status to CTI Biopharma's pacritinib NDA

CTI BioPharma initiated buy at Stifel; cites potential in myelofibrosis

CTI BioPharma Corp. Contemplates Bankruptcy

CTI BioPharma Corp. to Report Q4, 2020 Results on Mar 17, 2021

CTI BioPharma: Accelerated Approval Pathway Looks Attractive

Cti Biopharma Corp. Announces Publication of Article Highlighting Pacritinib Data from the Pac203 Phase 2 Study in Myelofibrosis in Blood Advances

CTI BioPharma Corp. Contemplates Bankruptcy

CTI BioPharma Corp. to Report Q3, 2020 Results on Nov 10, 2020

CTI BioPharma Corp. Initiates Rolling Submission of New Drug Application for Pacritinib in Myelofibrosis Patients with Severe Thrombocytopenia

CTI BioPharma to Submit a New Drug Application (NDA) for the Accelerated Approval of Pacritinib for the Treatment of Myelofibrosis Patients with Severe Thrombocytopenia

CTI BioPharma Corp. Contemplates Bankruptcy

Earnings released

New 90-day high - US$1.60

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin